Compare IH & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IH | FATE |
|---|---|---|
| Founded | 1996 | 2007 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.0M | 124.6M |
| IPO Year | 2020 | 2013 |
| Metric | IH | FATE |
|---|---|---|
| Price | $1.84 | $1.23 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $3.92 |
| AVG Volume (30 Days) | 14.4K | ★ 1.8M |
| Earning Date | 12-29-2025 | 03-04-2026 |
| Dividend Yield | ★ 4.62% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $119,261,855.00 | $7,137,000.00 |
| Revenue This Year | $39.02 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $0.66 |
| 52 Week High | $3.60 | $1.94 |
| Indicator | IH | FATE |
|---|---|---|
| Relative Strength Index (RSI) | 29.09 | 60.08 |
| Support Level | $1.80 | $1.02 |
| Resistance Level | $1.95 | $1.32 |
| Average True Range (ATR) | 0.07 | 0.08 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 10.80 | 71.30 |
iHuman Inc is a Chinese company that uses artificial intelligence to create technology-driven puzzle products for children, making parenting easier and children happier. The company offers a range of intellectual development products that are designed to make the child-rearing experience more manageable for parents while turning intellectual development into a fun journey for children. Its revenue is generated from subscription fees paid by users for premium content on their self-directed and interactive online applications, as well as offline products and other sources.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.